Floatz logo

TAMOXIFEN

CDH1-Related Diffuse Gastric And Lobular Breast Cancer Syndrome

European Institute of OncologySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CDH1-Related Diffuse Gastric And Lobular Breast Cancer Syndrome cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Royal Marsden NHS Foundation Trust
Phase 2B
Crizotinib
Royal Marsden NHS Foundation Trust
Phase 2B

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →